DELRAY BEACH, Fla., July 20, 2011 (GLOBE NEWSWIRE) -- PositiveID Corporation (“PositiveID” or “Company”) (Nasdaq:PSID), a developer of medical technologies for diabetes management, clinical diagnostics and bio-threat detection, announced today that it has been awarded a new international patent (WO2006/029387) “Handheld and Portable Microfluidic Device to Automatically Prepare Nucleic Acids for Analysis,” by the World Intellectual Property Organization. The new patent, awarded to the Company’s MicroFluidic Systems (“MFS”) subsidiary, covers the rapid, automated, and portable sample preparation of nucleic acids, such as DNA and RNA. This technology can be applied to the detection of pathogens in both field and clinical environments to quickly purify a patient or environmental sample for accurate diagnosis. The technology purifies samples to be run on commercial PCR instruments.
